Research confirms a coherent evidence base supporting the use of MGMT promoter methylation as a predictive biomarker for glioma treatment, with methylated patients experiencing significantly improved survival rates. As findings indicate that in vitro-matured oocytes exhibit higher methylation levels compared to in vivo counterparts, the next phase will focus on designing targeted experiments to leverage these insights in clinical protocols. With an overall low risk posture and aligned results across studies, the integration of methylation status into personalized medicine strategies appears promising.